产品封面图

NK-92

收藏
  • 询价
  • 2025年12月25日
    avatar
    15金牌会员
  • 企业认证

    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 细胞形态

      淋巴样

    • 库存

      大量

    • 运输方式

      冻存运输

    • 年限

      50 years

    • 生长状态

      悬浮生长,多细胞聚集

    • 物种来源

    • 是否是肿瘤细胞

      1

    • 细胞类型

      其他细胞类型

    • 相关疾病

      其他疾病

    • ATCC Number

      CRL-2407™

    Designations: NK-92
    Depositors:  Conkwest Inc.
    Biosafety Level: 2
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: suspension, multicell aggregates
    Organism: Homo sapiens deposited as human
    Morphology: lymphoblast

    Source: Disease: malignant non-Hodgkin's lymphoma
    Cell Type: natural killer cell; NK cell;
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
    Applications: transfection host
    Antigen Expression: CD2 +, CD7 +, CD11a +, CD28 + , CD45 +, CD54 +, CD56 +, CD1 -, CD3 -, CD4 -, CD5 -, CD8 -, CD10 -, CD14 -, CD16 -, CD19 -, CD20 -, CD23 -, CD34 -, HLA-DR -
    DNA Profile (STR): Amelogenin: X,Y
    CSF1PO: 11,12
    D13S317: 9,12
    D16S539: 11,12
    D5S818: 12,13
    D7S820: 10,11
    THO1: 6,9.3
    TPOX: 8
    vWA: 18
    Age: 50 years
    Gender: male
    Ethnicity: Caucasian, White
    Comments: NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. [38894 ]
    The cell line is dependent on the presence of recombinant Il-2 and a dose as low as 10 U/ml is sufficient to maintain proliferation; cells will die within 72 hours in the absence of IL-2. [38894 ]
    The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays. [38894 ]
    NK-92 cells (after irradiation to prevent proliferation) can be used effectively for immunological ex vivo purging of leukemia from blood without compromising hematopoietic cell function. [38896 ]
    NK-92 cells have the following characteristics: surfacemarker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4,CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. [38894 ]
    Propagation: ATCC complete growth medium: The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; 100-200 U/ml recombinant IL-2; adjust to a final concentration of 12.5% horse serum and 12.5% fetal bovine serum.
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Temperature: 37.0°C
    Growth Conditions: Successful growth of this cell line is very dependent upon the quality of IL-2 used in the growth medium. ATCC recommends using the highest quality IL-2 available.
    Subculturing: Protocol: Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 2 to 3 X 10(5) viable cells/ml. Pipet the cells up and down on the back of the flask every 2-3 days to produce a single cell suspension.
    NK-92 cells are extremely sensitive to overgrowth and media exhaustion.
    Medium Renewal: Replace with fresh medium every 2 to 3 days (depending on cell density)
    Preservation: Freeze medium: 50% FBS; 40% complete growth medium ; 10% DMSO.
    Storage temperature: liquid nitrogen vapor phase
    Related Products: recommended serum:ATCC 30-2020
    recommended serum:ATCC 30-2040
    derivative:ATCC CRL-2408
    References: 38894: Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260
    38896: Klingemann HG, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301
    38969: Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666
    39852: Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869
    39854: Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151
    39855: Yan Y, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753
    39857: Maki G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501
    39861: Nagashima S, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023
    40184: Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验
    • Persongen 新型 NK 细胞扩增技术

      NK细胞又称为自然杀伤细胞,属于大颗粒淋巴细胞,来源于骨髓,占外周血淋巴细胞的5%~15%,是重要的免疫细胞。科学家在1975年首次鉴定到了NK细胞,这类细胞能够在缺少T、B细胞的情况下直接杀伤肿瘤细胞。与具有细胞毒性的CD8+T细胞不同,NK细胞杀伤肿瘤细胞时不需要预先致敏可以直接杀伤MHC阴性的肿瘤细胞,这使得NK细胞在过继细胞免疫治疗中被广泛应用。但NK细胞在外周血淋巴细胞中所占的比例较低,所以有必要建立一种NK细胞体外扩增技术,用于研究NK细胞的功能并为肿瘤的细胞免疫治疗奠定

    • 【进展|热点】JEM: NK细胞的新角色

      【推荐指数】 ★★★ 【文章来源】 Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection Journal of Experimental Medicine, Vol. 206, No. 10, 2235-2251 http://jem.rupress.org/cgi

    • NK 细胞相关治疗策略的非临床研究模型选择

      近几年,以 T 细胞为靶点的免疫治疗策略的研究一直居于肿瘤免疫治疗研究热点榜高位,当大家都想在这个领域分一杯羹时,新的尝试开始逐渐挤入热度的核心,其中不乏以 NK 细胞为靶点的治疗方法的探索。与 T 细胞的研究相比,NK 细胞相关研究出了「抄作业」之外,还有什么特殊之处呢? IL15 是 NK 细胞发育所必须的细胞因子 NK 细胞又称自然杀伤细胞,属于天然免疫系统的核心细胞,是机体内重要的免疫细胞。NK 细胞是人体抵抗癌细胞和病毒感染的第一道防线,可非特异性直接杀伤肿瘤细胞,这种天然杀伤

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1800
    博辉生物科技(广州)有限公司
    2026年01月21日询价
    询价
    ATCC细胞库
    2025年12月20日询价
    ¥1280
    上海康朗生物科技有限公司
    2026年01月21日询价
    ¥680
    上海联迈生物工程有限公司
    2025年10月26日询价
    ¥2800
    上海酶研生物科技有限公司
    2026年01月08日询价
    NK-92
    询价